小儿科抗癫痫药物市场按药物类型、给药途径、分销管道和地区划分

2025 年全球小儿科抗癫痫药物市场规模估计为 14.782 亿美元，预计到 2032 年将达到 25.334 亿美元，2025 年至 2032 年的复合年增长率为 8.0%。

数字。 2025年小儿科抗癫痫药物市场占有率（按地区）

癫痫是一种常见的神经系统疾病，影响着全世界各个年龄层的人。然而，癫痫在儿童中更为常见，因为近 70% 的癫痫患者在成年之前就被诊断出来。抗癫痫药物在控制癫痫发作和改善癫痫的儿科患者的生活品质方面发挥着重要作用。这些药物透过控制大脑中异常神经细胞的放电和同步来预防癫痫发作。最近的趋势包括经过广泛研究后开发和核准新一代小儿科抗癫痫药物，这些药物更有效、副作用更少。这对儿童癫痫患者的药物顺从性和治疗结果有正面的影响。儿童癫痫的原因包括创伤、出生併发症和遗传性疾病。由脑膜炎等脑部感染疾病引起的癫痫称为症状性癫痫，而与遗传相关的疾病称为特发性癫痫。

市场动态

儿童癫痫盛行率的不断上升推动了全球小儿科抗癫痫药物市场的发展。根据世界卫生组织 (WHO) 的数据，全球约有 1% 的儿童患有癫痫。其他推动市场成长的因素包括医疗保健成本的增加、对癫痫治疗的认识的提高以及新型抗癫痫药物的推出。然而，也存在市场限制，例如市场开发成本高以及儿科药物核准规定严格。此外，抗癫痫药物对儿童神经系统的副作用也是一个问题。另一方面，疾病修正治疗的研发和个人化抗癫痫药物治疗方案的开发为新兴市场进入者带来了显着的机会。

本研究的主要特点

• 本报告对全球小儿科抗癫痫药物市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
• 全球小儿科抗癫痫药物市场的主要公司概况是根据公司亮点、产品系列、主要亮点、业绩和策略等参数进行的。
• 本研究涉及的主要企业包括赛诺菲、Eisai、辉瑞、UCB SA、Sunovion Pharmaceuticals、雅培、Jazz Pharmaceuticals、Ovid Therapeutics Inc.、SK BIOPHARMACEUTICALS、Alexza Pharmaceuticals, Inc.、Taisho Pharmaceutical Holdings、Marinus Pharmaceutical) Industries Ltd.。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。
• 全球小儿科抗癫痫药物市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
• 相关人员可以透过用于分析全球小儿科抗癫痫药物市场的各种策略矩阵来简化决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
• 神经系统疾病发生率增加
• 增加研发活动
  • 限制因素
• 监管机构增加产品召回
• 抗癫痫药物的副作用
  • 市场机会
• 尚未开发的新兴市场
• 标靶治疗需求不断增长
• 影响分析
• 监管指南
• 产品发布
• 主要进展
• PEST分析
• 波特分析
• 监管情景
• 合併与收购
• 製造商收益
• 各国医疗保健支出

第四章全球小儿科抗癫痫药物市场-COVID-19影响分析

• 整体影响
• 政府倡议
• COVID-19 市场影响

第五章 2020 年至 2032 年小儿科抗癫痫药物市场（依药物类型）

• 第一代抗癫痫药物
• 第二代抗癫痫药物
• 第三代抗癫痫药物

第六章小儿科抗癫痫药物市场（依给药途径），2020 年至 2032 年

• 口服
• 注射
• 其他（鼻腔等）

第七章小儿科抗癫痫药物市场（依分销管道划分），2020 年至 2032 年

• 医院药房
• 零售药局
• 网路药局

第 8 章小儿科抗癫痫药物市场（按地区划分），2020-2032 年

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第九章 竞争态势

• Sanofi
• Eisai Co., Ltd.
• Pfizer Inc.
  • Company Highlight
• UCB SA
• Sunovion Pharmaceuticals Inc.
• Abbott
• Jazz Pharmaceuticals plc
• Ovid Therapeutics Inc.
• SK BIOPHARMACEUTICALS
• Alexza Pharmaceuticals, Inc.
• Taisho Pharmaceutical Holdings Co., Ltd.
• Marinus Pharmaceuticals, Inc.
• Xenon Pharmaceuticals Inc.
• Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.

第 10 章 章节

• 调查方法
• 关于出版商

Global Anti-Epileptic Drugs for Pediatrics Market is estimated to be valued at USD 1,478.2 Mn in 2025 and is expected to reach USD 2,533.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2032.

Figure. Anti-Epileptic Drugs For Pediatrics Market Share (%), By Region 2025

Epilepsy is a common neurological disorder that affects people of all ages globally. However, it is more prevalent in children as almost 70% of epilepsy cases are diagnosed before reaching adulthood. Anti-epileptic drugs play a crucial role in managing seizures and improving quality of life for pediatric patients suffering from epilepsy. These medications work by controlling abnormal neuronal firing and synchrony in the brain to prevent seizures. In recent years, extensive research has led to the development and approval of newer generation anti-epileptic drugs that are more effective and have less side effects than the earlier drugs for pediatric use. This has positively impacted medication adherence and treatment outcomes for children with epilepsy. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while a genetics related condition is called idiopathic epilepsy.

Market Dynamics

The global anti-epileptic drugs for pediatrics market is driven by the growing prevalence of epilepsy among children. According to the World Health Organization (WHO), epilepsy affects around 1% of children worldwide. Besides this, factors such as increasing healthcare expenditures, rising awareness about epilepsy treatment, and introduction of newer anti-epileptic drugs are fueling the market growth. However, the market faces certain restraints such as high costs associated with drug development and stringent regulations for the approval of pediatric drugs. Moreover, adverse effects of anti-epileptic drugs on developing neurological system of children poses challenges. On the positive side, ongoing research on disease modifying therapies and development of personalized anti-epileptic drug regimens present notable opportunities for market players in the future.

Key features of the study:

• This report provides an in-depth analysis of the global anti-epileptic drugs for pediatrics market, and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anti-epileptic drugs for pediatrics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as part of this study include Sanofi, Eisai Co., Ltd., Pfizer Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Abbott, Jazz Pharmaceuticals plc, Ovid Therapeutics Inc., SK BIOPHARMACEUTICALS, Alexza Pharmaceuticals, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Marinus Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., H. Lundbeck A/S, and Teva Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics
• The global anti-epileptic drugs for pediatrics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs for pediatrics market

Detailed Segmentation:

• Global Anti-Epileptic Drugs for Pediatrics Market, Drug Type:
  • First generation anti-epileptic drugs
  • Second generation anti-epileptic drugs
  • Third generation anti-epileptic drugs
• Global Anti-Epileptic Drugs for Pediatrics Market, Route of Administration:
  • Oral
  • Injectable
  • Others (Nasal, etc.)
• Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Anti-Epileptic Drugs for Pediatrics Market, By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles
  • Sanofi
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • UCB S.A.
  • Sunovion Pharmaceuticals Inc.
  • Abbott
  • Jazz Pharmaceuticals plc
  • Ovid Therapeutics Inc.
  • SK BIOPHARMACEUTICALS
  • Alexza Pharmaceuticals, Inc.
  • Taisho Pharmaceutical Holdings Co., Ltd.
  • Xenon Pharmaceuticals Inc.
  • Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trend Analysis

• Market Dynamics
  • Drivers
• Increasing incidence of neurological disorders
• Increasing research and development activities
  • Restraints
• Increasing product recalls by regulatory authorities
• Side effects of anti-epileptic drugs
  • Market Opportunities
• Untapped emerging markets
• The rising demand for targeted therapy
• Impact Analysis
• Regulatory Guidelines
• Product Launches
• Key Development
• PEST Analysis
• PORTER's Analysis
• Regulatory Scenario
• Mergers and Acquisitions
• Manufacturer Revenue
• Healthcare Spending by Country

4. Global Anti-Epileptic Drugs for Pediatrics Market - COVID-19 Impact Analysis

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, 2020-2032, (US$ Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• First generation anti-epileptic drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Second generation anti-epileptic drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Third generation anti-epileptic drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global Anti-Epileptic Drugs for Pediatrics Market, By Route of Administration, 2020-2032, (US$ Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Others (Nasal, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global Anti-Epileptic Drugs for Pediatrics Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eisai Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlight
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• UCB S.A.
• Sunovion Pharmaceuticals Inc.
• Abbott
• Jazz Pharmaceuticals plc
• Ovid Therapeutics Inc.
• SK BIOPHARMACEUTICALS
• Alexza Pharmaceuticals, Inc.
• Taisho Pharmaceutical Holdings Co., Ltd.
• Marinus Pharmaceuticals, Inc.
• Xenon Pharmaceuticals Inc.
• Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.

10. Section

• Research Methodology
• About Us